These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21886169)

  • 1. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.
    Krause G; Patz M; Isaeva P; Wigger M; Baki I; Vondey V; Kerwien S; Kuckertz M; Brinker R; Claasen J; Frenzel LP; Wendtner CM; Heider KH; Hallek M
    Leukemia; 2012 Mar; 26(3):546-9. PubMed ID: 21886169
    [No Abstract]   [Full Text] [Related]  

  • 2. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
    Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
    Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
    Rafiq S; Siadak A; Butchar JP; Cheney C; Lozanski G; Jacob NK; Lapalombella R; McGourty J; Moledor M; Lowe R; Setter B; Jones J; Flynn JM; Andritsos L; Devine S; Mo X; Jarjoura D; Tridandapani S; Algate P; Byrd JC; Muthusamy N
    MAbs; 2013; 5(5):723-35. PubMed ID: 23883821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DuoHexaBody-CD37
    Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW
    Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
    Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
    Robak T
    Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
    Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
    Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
    Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD37 antibodies for chronic lymphocytic leukemia.
    Robak T; Robak P
    Expert Opin Biol Ther; 2014 May; 14(5):651-61. PubMed ID: 24555705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
    Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
    Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
    Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
    Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
    Lefebvre ML; Krause SW; Salcedo M; Nardin A
    J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
    Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
    Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemia-associated changes identified by quantitative flow cytometry. III. B-cell gating in CD37/kappa/lambda clonality test.
    Peters RE; Janossy G; Ivory K; al-Ismail S; Mercolino T
    Leukemia; 1994 Nov; 8(11):1864-70. PubMed ID: 7967732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.
    Krause G; Baki I; Kerwien S; Knödgen E; Neumann L; Göckeritz E; Landwehr T; Heider KH; Hallek M
    Br J Haematol; 2016 Jun; 173(5):791-4. PubMed ID: 26271483
    [No Abstract]   [Full Text] [Related]  

  • 16. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
    Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
    Robak T
    Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
    Robak T; Robak P; Smolewski P
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1383-90. PubMed ID: 19943209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
    Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C
    J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.